<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Therapeutic options for COVID-19 [
   <xref ref-type="bibr" rid="CR59">59</xref>]
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Diseases</th>
    <th align="left">Drug targets</th>
    <th align="left">Antiviral agents</th>
    <th align="left">Status</th>
    <th align="left">Target pathogens</th>
    <th align="left">RefS.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">SARS-CoV-2; MERS-CoV</td>
    <td align="left">Spike glycoprotein</td>
    <td align="left">Nafamostat</td>
    <td align="left">Approved</td>
    <td align="left">Anticoagulant therapy in Asian countries</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR99">99</xref>, 
     <xref ref-type="bibr" rid="CR100">100</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="3">SARS-CoV-2; SARS-CoV; MERS-CoV</td>
    <td align="left" rowspan="3">Interferon response</td>
    <td align="left" rowspan="3">Recombinant interferons</td>
    <td align="left">Approved</td>
    <td align="left">Metastatic renal cell carcinoma (IFN-α2a)</td>
    <td align="left" rowspan="3">[
     <xref ref-type="bibr" rid="CR101">101</xref>–
     <xref ref-type="bibr" rid="CR103">103</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Approved</td>
    <td align="left">Melanoma (IFN-α2b)</td>
   </tr>
   <tr>
    <td align="left">Approved</td>
    <td align="left">Multiple sclerosis (IFN-β1a, 1b), chronic granulomatous disease (IFN-γ)</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">SARS-CoV-2; SARS-CoV; MERS-CoV</td>
    <td align="left" rowspan="2">Endosomal acidification</td>
    <td align="left" rowspan="2">Chloroquine</td>
    <td align="left">Approved</td>
    <td align="left">Malaria and certain amoeba infections</td>
    <td align="left" rowspan="2">[
     <xref ref-type="bibr" rid="CR99">99</xref>, 
     <xref ref-type="bibr" rid="CR104">104</xref>–
     <xref ref-type="bibr" rid="CR106">106</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Open-label trial</td>
    <td align="left">SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="left">Broad-spectrum(e.g. coronaviruses; SARS-CoV-2)</td>
    <td align="left">Interferon response</td>
    <td align="left">Nitazoxanide</td>
    <td align="left">Approved</td>
    <td align="left">Diarrhea</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR99">99</xref>, 
     <xref ref-type="bibr" rid="CR107">107</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Broad-spectrum (HCoV-229E)</td>
    <td align="left">Interferon response</td>
    <td align="left">Cyclophilin inhibitors (Compound 30)</td>
    <td align="left">Preclinical</td>
    <td align="left">–</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR108">108</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Influenza; SARS- CoV-2</td>
    <td align="left" rowspan="2">RdRp</td>
    <td align="left" rowspan="2">Favipiravir</td>
    <td align="left">Approved</td>
    <td align="left">Influenza</td>
    <td align="left" rowspan="2">[
     <xref ref-type="bibr" rid="CR99">99</xref>, 
     <xref ref-type="bibr" rid="CR109">109</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Randomized trial</td>
    <td align="left">SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="left">SARS-CoV; SARS-CoV-2; RSV; HCV MERS-CoV</td>
    <td align="left" rowspan="2">RdRp</td>
    <td align="left" rowspan="2">Ribavirin</td>
    <td align="left">Approved</td>
    <td align="left">HCV and RSV</td>
    <td align="left" rowspan="2">[
     <xref ref-type="bibr" rid="CR99">99</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left">Randomized trial</td>
    <td align="left">SARS SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="left">SARS-CoV-2</td>
    <td align="left" rowspan="3">RdRp</td>
    <td align="left">Penciclovir</td>
    <td align="left">Approved</td>
    <td align="left">HSV</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR99">99</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="2">SARS-CoV-2; MERS-CoV; SARS-CoV</td>
    <td align="left" rowspan="2">Remdesivir (GS-5734)</td>
    <td align="left">Phase 3</td>
    <td align="left">SARS-CoV-2</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR99">99</xref>, 
     <xref ref-type="bibr" rid="CR109">109</xref>, 
     <xref ref-type="bibr" rid="CR110">110</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Phase 1</td>
    <td align="left">Ebola</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left" rowspan="2">SARS-CoV-2; MERS-CoV; SARS-CoV; HCoV-229E; HIV; HPV</td>
    <td align="left" rowspan="2">3CLpro</td>
    <td align="left" rowspan="2">Lopinavir</td>
    <td align="left">Approved</td>
    <td align="left">HIV</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR110">110</xref>] [
     <xref ref-type="bibr" rid="CR103">103</xref>, 
     <xref ref-type="bibr" rid="CR111">111</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Phase 3</td>
    <td align="left">SARS-CoV-2</td>
    <td align="left"/>
   </tr>
  </tbody>
 </table>
</table-wrap>
